mesothelioma
A2 Bio Begins Testing Cell Therapy A2B694 in Solid Tumor Clinical Trial
The Phase I/II EVEREST-2 trial will include patients with advanced mesothelin-expressing cancers that have lost HLA-A*02 expression.
The deal will bring new therapy candidates, including MorphoSys' EZH2 and EZH1 inhibitor tulmimetostat, into Novartis' oncology pipeline.
Newly Identified Biomarkers in Breath of Mesothelioma Patients May Predict Treatment Response
Premium
Researchers reported at the World Conference on Lung Cancer on six volatile organic compounds in exhaled breath associated with response to chemo or immunotherapy.
Verismo Doses First Solid Tumor Patient With Autologous SynKIR-110 Cell Therapy
The University of Pennsylvania spinout has begun a first-in-human trial of the treatment in patients with advanced ovarian cancer, cholangiocarcinoma, and mesothelioma.
Verismo Nets $17M in Second Pre-Series A Round of Financing
The UPenn spinout has now raised a total of $50 million since launching, which it is using to advance its autologous cell therapies for solid and hematologic cancers.